Table 1.

Characteristics of eyes that switched treatments from ranibizumab to aflibercept at the time of this switch, after at least 12 months of ranibizumab

	Switching eyes
Number of eyes	384
Mean months in treatment prior to switch (SD)	39.8 (20)
Mean VA at switch—logMAR letters (SD)	63.4 (15.9)
Median treatment interval at switch—days (Q1 and Q3)	42 (31 and 70)
Proportion with CNV graded active at switch (%)	80

CNV, choroidal neovascular membrane; logMAR, logarithm of the minimum angle of resolution; Q1, first quartile; Q3, third quartile; VA, visual acuity.